KI
The startup develops hydrogen peroxide-based radiosensitizers delivered via prefilled syringes for intratumoral injection prior to radiotherapy. This approach enhances the sensitivity of hypoxic tumors to radiation by inactivating antioxidative enzymes, thereby improving the effectiveness of cancer treatment.
Updated 3 months ago
Funding
$24.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops hydrogen peroxide-based radiosensitizers delivered via prefilled syringes for intratumoral injection prior to radiotherapy. This approach enhances the sensitivity of hypoxic tumors to radiation by inactivating antioxidative enzymes, thereby improving the effectiveness of cancer treatment.